BioLargo's Revenue Plummets, Net Loss Widens Amid Going Concern Doubts

TL;DR

**BLGO is bleeding cash and revenue, making it a high-risk bet unless they can pull a rabbit out of a hat with new funding or a massive sales surge.**

AI Summary

BIOLARGO, INC. (BLGO) reported a significant decline in revenue and an increased net loss for the six months ended June 30, 2025. Total revenue decreased by 38.1% to $6.046 million from $9.773 million in the prior year period, primarily driven by a 49.1% drop in product revenue from $9.464 million to $4.809 million. The company's net loss widened substantially to $3.803 million for the six months ended June 30, 2025, compared to a net loss of $1.555 million for the same period in 2024. Operating loss also increased to $3.664 million from $1.653 million year-over-year. Despite these losses, current assets increased to $9.187 million from $7.137 million at December 31, 2024, largely due to a new note receivable of $3.486 million. However, the company used $3.948 million in net cash from operating activities, a significant increase from the $330,000 provided by operating activities in the prior year, raising substantial doubt about its ability to continue as a going concern without further investment or increased revenues.

Why It Matters

This 10-Q filing reveals a critical financial deterioration for BioLargo, with revenue nearly halved and net losses more than doubled. For investors, the 'going concern' warning is paramount, indicating a high risk of financial instability and potential dilution if new capital is raised. Employees face uncertainty regarding job security, while customers might question the long-term viability of BioLargo's innovative environmental solutions. In a competitive market for PFAS and water treatment technologies, BioLargo's struggles could open doors for rivals, impacting its market position and future growth prospects.

Risk Assessment

Risk Level: high — The company explicitly states, "The foregoing factors raise substantial doubt about our ability to continue as a going concern." This is supported by a net loss of $3.803 million and $3.948 million in net cash used in operating activities for the six months ended June 30, 2025, compared to a net loss of $1.555 million and $330,000 net cash provided by operating activities in the prior year.

Analyst Insight

Investors should exercise extreme caution and consider divesting or avoiding BLGO shares due to the explicit 'going concern' warning and significant financial deterioration. Monitor closely for any announcements regarding substantial new financing or a dramatic turnaround in revenue generation, as these are critical for the company's survival.

Financial Highlights

debt To Equity

0.70

revenue

$6,046,000

operating Margin

-60.6%

total Assets

$12,499,000

total Debt

$2,083,000

net Income

-$3,803,000

eps

-$0.008

gross Margin

39.9%

cash Position

$3,471,000

revenue Growth

-38.1%

Revenue Breakdown

Key Numbers

• $6.046M — Total Revenue (Decreased by 38.1% for the six months ended June 30, 2025, from $9.773 million in 2024.)
• $3.803M — Net Loss (Increased significantly for the six months ended June 30, 2025, from $1.555 million in 2024.)
• $3.948M — Net Cash Used in Operating Activities (A substantial outflow for the six months ended June 30, 2025, compared to $330,000 provided in 2024.)
• $3.471M — Cash and Cash Equivalents (As of June 30, 2025, a slight decrease from $3.548 million at December 31, 2024.)
• $3.486M — Note Receivable (A new current asset as of June 30, 2025, contributing to increased current assets.)
• 308,989,058 — Common Stock Outstanding (As of August 12, 2025, indicating potential dilution from prior periods.)
• $0.008 — Loss per share (For the six months ended June 30, 2025, compared to $0.003 in 2024.)

Key Players & Entities

• BIOLARGO, INC. (company) — registrant
• Clyra Medical Technologies, Inc. (company) — partially owned subsidiary
• BioLargo Engineering Science and Technologies, LLC (company) — partially owned subsidiary
• BioLargo Energy Technologies, Inc. (company) — partially owned subsidiary
• Delaware (regulator) — state of incorporation
• Securities and Exchange Commission (regulator) — filing oversight
• PFAS (other) — environmental problem addressed by company
• Bloomberg (company) — publisher of analysis

FAQ

Risk Factors

• Deteriorating Financial Performance and Going Concern [high — financial]: The company experienced a 38.1% revenue decline and a significant increase in net loss to $3.803 million for the six months ended June 30, 2025. Furthermore, operating activities consumed $3.948 million in cash, a stark contrast to the $330,000 generated in the prior year. This severe cash burn raises substantial doubt about the company's ability to continue as a going concern without additional financing or revenue improvements.
• Increased Debt and Liabilities [medium — financial]: Total liabilities increased from $4.457 million at December 31, 2024, to $6.439 million at June 30, 2025. This rise is largely driven by increases in Clyra Medical debt obligations and accounts payable. The growing debt burden, coupled with declining revenues, puts additional financial strain on the company.
• Dependence on Product Revenue [high — operational]: The significant 49.1% drop in product revenue to $4.809 million for the six months ended June 30, 2025, highlights a critical over-reliance on this segment. The inability of service revenue growth to compensate for this decline indicates potential issues with product sales strategy, market demand, or competitive pressures.
• Increased Operating Loss [high — financial]: The operating loss widened to $3.664 million for the six months ended June 30, 2025, from $1.653 million in the prior year. This indicates that the core operations are becoming less efficient or are facing increased costs relative to revenue, exacerbating the net loss.

Industry Context

BioLargo, Inc. operates in the environmental technology and healthcare sectors, focusing on solutions for water treatment and infection control. The industry is characterized by innovation, regulatory oversight, and competition from established players and emerging technologies. Companies in this space often face long sales cycles and require significant R&D investment.

Regulatory Implications

As a company involved in potentially regulated areas like water treatment and medical devices, BioLargo faces compliance risks. Adherence to environmental standards, health regulations (e.g., FDA if applicable), and product safety is critical. Non-compliance can lead to fines, product recalls, and reputational damage.

What Investors Should Do

1. Monitor cash burn and future financing needs.
2. Analyze the sustainability of service revenue growth.
3. Evaluate the impact of the new note receivable.

Key Dates

• 2025-06-30: Six Months Ended — Period reflects a significant revenue decline and increased net loss, raising going concern issues.
• 2025-06-30: Balance Sheet Date — Current assets increased due to a new note receivable, but cash position slightly decreased. Total liabilities increased significantly.
• 2024-12-31: Prior Year End — Provides a baseline for comparison of financial performance and position changes.

Glossary

Accumulated deficit

The total net losses of a company since its inception that have not been offset by net income. (Indicates the company has historically incurred more losses than profits, standing at ($151,848,000) as of June 30, 2025.)

Note receivable

A formal written promise from a debtor to pay a specified sum of money to a creditor on demand or at a specified future date. (A new note receivable of $3,486,000 was added as a current asset, boosting total current assets but also representing funds not immediately available as cash.)

Going concern

An assumption that a company will continue to operate for the foreseeable future, typically at least the next 12 months. (The company's financial performance and cash flow raise substantial doubt about its ability to continue as a going concern.)

Cost of revenue

The direct costs attributable to the production or purchase of the goods or services sold by a company. (For the six months ended June 30, 2025, cost of revenue was $3,136,000, representing a significant portion of total revenue.)

Year-Over-Year Comparison

Compared to the six months ended June 30, 2024, BioLargo, Inc. has seen a substantial decline in financial performance. Total revenue dropped by 38.1% to $6.046 million, primarily due to a 49.1% decrease in product revenue. The company's net loss widened significantly from $1.555 million to $3.803 million, and operating cash flow turned from a positive $330,000 to a negative $3.948 million. These metrics collectively point to a deteriorating financial condition and increased operational challenges.

Key Financial Figures

• $94 — bligations, net of current and discount $94 and $80 971 352 Operating lease liab
• $80 — ns, net of current and discount $94 and $80 971 352 Operating lease liabilities,
• $250,000 — nsurance Corporation insurance limit of $250,000 per owner per bank, and during such tim

Filing Documents

• blgo20250630_10q.htm (10-Q) — 2043KB
• ex_850596.htm (EX-10.17) — 95KB
• ex_850597.htm (EX-10.18) — 20KB
• ex_850598.htm (EX-10.19) — 215KB
• ex_850599.htm (EX-10.20) — 351KB
• ex_821169.htm (EX-31.1) — 10KB
• ex_821170.htm (EX-31.2) — 10KB
• ex_821171.htm (EX-32) — 10KB
• sig01.jpg (GRAPHIC) — 3KB
• sig02.jpg (GRAPHIC) — 3KB
• 0001437749-25-027021.txt ( ) — 11494KB
• blgo-20250630.xsd (EX-101.SCH) — 77KB
• blgo-20250630_cal.xml (EX-101.CAL) — 52KB
• blgo-20250630_def.xml (EX-101.DEF) — 597KB
• blgo-20250630_lab.xml (EX-101.LAB) — 477KB
• blgo-20250630_pre.xml (EX-101.PRE) — 632KB
• blgo20250630_10q_htm.xml (XML) — 2188KB

Financial Statements

Financial Statements 1 Item 2

Management's Discussion and Analysis and Financial Condition and Results of Operations

Management's Discussion and Analysis and Financial Condition and Results of Operations 27 Item 4

Controls and Procedures

Controls and Procedures 38 PART II Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 40 Item 5 Other Information 40 Item 6 Exhibits 41

Signatures

Signatures 43 Table of Contents

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements - 1 - Table of Contents BIOLARGO, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except for share and per share data) June 30, 2025 December 31, (unaudited) 2024 Assets Current assets: Cash and cash equivalents $ 3,471 $ 3,548 Accounts receivable, net of allowances 1,735 3,168 Note receivable 3,486 — Inventories 444 330 Prepaid expenses and other current assets 51 91 Total current assets 9,187 7,137 Equipment and leasehold improvements, net 1,664 1,742 Note receivable, net of current 86 — Other non-current assets 102 95 Operating lease right-of-use assets, net 937 992 Financing lease right-of-use asset, net 418 451 Clyra Medical note receivable 82 82 Investment in South Korean joint venture 23 14 Total assets $ 12,499 $ 10,513 Liabilities and stockholders' equity Current liabilities: Accounts payable and accrued expenses $ 1,430 $ 946 Clyra Medical accounts payable and accrued expenses 1,183 867 Clyra Medical debt obligations, net of discount $ 161 and $ 80 1,033 486 Debt obligations 83 66 Operating lease liabilities 105 105 Finance lease liability 88 88 Deposits 158 90 Total current liabilities 4,080 2,648 Long-term liabilities: Debt obligations, net of current 199 175 Clyra Medical debt obligations, net of current and discount $94 and $80 971 352 Operating lease liabilities, net of current 872 922 Finance lease liability, net of current 317 360 Total long-term liabilities 2,359 1,809 Total liabilities 6,439 4,457 STOCKHOLDERS' EQUITY: Preferred Series A, $ 0.00067 Par Value, 50,000,000 Shares Authorized, no Shares Issued and Outstanding, at June 30, 2025 and December 31, 2024 — — Common stock, $ 0.00067 Par Value, 550,000,000 Shares Authorized, 306,752,661 and 301,274,243 Shares Issued, at June 30, 2025 and December 31, 2024 205 202 Additional paid-in capital 160,601 158,332 Accumulated def

View Full Filing

View this 10-Q filing on SEC EDGAR